How do immune cells in the pancreas affect insulin production in people with obesity and Type-2 diabetes? Researchers at the Indian Institute of Technology (IIT)-Kanpur have uncovered a molecular pathway through which immune cells can rapidly suppress insulin release, offering a potential new target for developing diabetes therapies.
The study, published in the Journal of Clinical Investigation, reveals that immune cells called macrophages can switch off insulin secretion by neighbouring pancreatic beta cells within minutes. Unlike the gradual damage caused by prolonged inflammation, this process directly interferes with the cells’ insulin-producing machinery.
How Do Immune Cells Suppress Insulin Release?
The researchers found that macrophages release sphingolipids, a class of fats that interfere with insulin secretion. This mechanism differs from the inflammatory proteins traditionally linked to obesity-related pancreatic damage.
The team identified GPR18, a receptor present on macrophages, as a key trigger. When activated, this receptor prompts macrophages to release sphingolipids. Neighbouring beta cells then absorb these fats through a surface transporter, disrupting their ability to release insulin.
Blocking the Pathway May Restore Insulin Secretion
Using precision genetic techniques, the researchers demonstrated that activating this molecular pathway reduced insulin secretion in mouse models. However, switching it off improved insulin release. Blocking GPR18 and other components of the pathway also helped restore insulin secretion.
Furthermore, the research team, in collaboration with the Indiana Biosciences Research Institute in the US, confirmed that the same pathway was present and active in human pancreatic tissue. Experiments using donated human tissue also showed that activating the pathway suppressed insulin secretion.
New Target for Future Diabetes Therapies
The findings could open new possibilities for developing treatments that protect insulin production in people with obesity and Type-2 diabetes. By targeting the GPR18 pathway and its associated molecular processes, future therapies may help preserve the insulin-producing function of pancreatic beta cells.
Although the research does not offer an immediate treatment for diabetes, it identifies a promising molecular target for future drug development. As reported by thehindu.com, the study was conducted by researchers at the Indian Institute of Technology (IIT)-Kanpur and published in the Journal of Clinical Investigation.



















